Study identifier:BY9010/M1-506
ClinicalTrials.gov identifier:NCT00314509
EudraCT identifier:N/A
CTIS identifier:N/A
ADVICE: A dose range finding study of formoterol administered once daily in the evening in combination with ciclesonide using the Ultrahaler™ versus monotherapy of each drug in asthmatic patients
asthma
Phase 2
No
Ciclesonide/Formoterol Combination
All
240
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma. The study duration consists of a baseline period (2 to 3 weeks) and a treatment period (8 weeks). The study will provide further data on safety and tolerability of ciclesonide/formoterol fumarate.
Location
Location
Montpellier, France, 34295
Location
Grenoble, France, 38100
Location
Berlin, Germany, 14050
Location
Rüdersdorf, Germany, 15562
Location
Großhansdorf, Germany, 22927
Location
Mainz, Germany, 55131
Location
Wiesbaden, Germany, 65187
Location
Budapest, Hungary, 1125
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.